Company Description
Novo Nordisk can tell diabetics where to stick it. One of the world's leading producers of insulin, Novo Nordisk also makes insulin analogues,...
Key Novo Nordisk Financials
| Company Type | Public - NYSE: NVO; Copenhagen: NOVO B Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $8,261.6 |
| 2007 Employees | 26,000 |
More Novo Nordisk Financials (11 pages)
Latest Novo Nordisk Jobs powered by Monster.com
- Pharma Field Sales - Diabetes Care Specialist (DCS) – Bellingham, WA
- Pharma Field Sales - Diabetes Care Specialist (DCS) – Longview, TX
- Pharma Field Sales - Diabetes Care Specialist (DCS) Coral Springs, FL
Rankings
- #348 in FT Global 500
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Novo Nordisk's competition across multiple industries
Top Novo Nordisk Competitors
Sponsored Links
The Business Directory
Novo Nordisk Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Sten Scheibye | Network | E-mail |
| President and CEO | Lars Rebien Sørensen | Network | E-mail |
| EVP and CFO | Jesper Brandgaard | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Novo Nordisk News
-
Novo Nordisk A/S ADR (NYSE:NVO) Weekly Earnings Information [Nelson Information - Weekly Domestic] (17 May 2008 04:00:00 EDT) - NOVO NORDISK A/S EPS Estimated At 14.47 [Nelson Information - Daily] (15 May 2008 21:15:00 EDT)
- NOVO NORDISK A/S Consensus Recommendation: HOLD [Nelson Information - Daily] (15 May 2008 21:15:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.